INmune Bio Investor Relations Material
Latest events
Q2 2025
INmune Bio
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from INmune Bio Inc
Access all reports
INmune Bio, Inc. is a clinical-stage immunotherapy company. The company focuses on reprogramming the patient's innate immune system to treat cancer, Alzheimer's disease and non-alcoholic steatohepatitis. It has several development programs, including INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; LivNate to treat patients with non-alcoholic steatohepatitis; and Quellor for cytokine release syndrome and complications of COVID-19
Key slides for INmune Bio Inc
Corporate Presentation
INmune Bio Inc
Corporate Presentation
INmune Bio Inc
Latest articles
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
Ticker symbol
INMB
Country
🇺🇸 United States